A prospective study conducted in an adult intensive care unit to measure the plasma concentration of citrate during continuous renal replacement therapy.

Assessment of the plasma concentration of citrate in critically ill patients undergoing continuous renal replacement therapy.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12616000515493

Acronym

ACCid HF

Enrollment

Registered

2016-04-21

Start date

2017-08-28

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary aim of the study is to quantify to plasma concentration of citrate when using RCA with CRRT. We expect to establish a mean and standard deviation for the plasma concentration. Our secondary aim is to measure citrate clearance across the haemofilter over time. We hope to show that this measure is sensitive enough to predict filter failure.

Interventions

Regional citrate anticoagulation (RCA) is currently the preferred method of anticoagulating the extracorporeal circuit used in continuous renal replacement therapy (CRRT). The citrate solution is infused into the blood before the filter and a residual amount circulates back into the patients bloodstream prior to metabolism by the liver. At present, surrogate measures of questionable utility are used to assess the presence or otherwise of citrate toxicity. In this study, participants undergoing CRRT using RCA will have blood and ultrafiltrate collected three times a day for the duration of their CRRT (approx. 7 days). These samples will be analysed to ascertain the plasma concentration of citrate and the clearance of citrate across the haemofilter membrane. Participants will be monitored in the usual way during treatment.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Clinical requirement for CRRT in patients admitted to the Intensive Care Unit (ICU).

Exclusion criteria

Age under 18 years Patients who are pregnant Patients with advanced liver disease (Childs C) Patients likely to die within 24 hours of admission the the ICU Known hypersensitivity or allergy to citrate compounds

Outcome results